Evidence map›Paper›PMID 39342352›Full record

ArticleOrphanet journal of rare diseases2024

Living with Pompe disease: results from a qualitative interview study with children and adolescents and their caregivers.

Moritz Ilan Truninger, Helene Werner, Markus Andreas Landolt, Andreas Hahn, Julia B Hennermann, Florian B Lagler, Dorothea Möslinger, Charlotte Pfrimmer, Marianne Rohrbach, Martina Huemer

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Moritz Ilan TruningerDivision of Metabolism, Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Steinwiesstrasse 75, Zürich, 8032, Switzerland.ORCID 0000-0001-6724-5019
Helene WernerDivision of Metabolism, Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Steinwiesstrasse 75, Zürich, 8032, Switzerland.ORCID 0000-0002-7081-7695
Markus Andreas LandoltDepartment of Psychosomatics and Psychiatry, University Children's Hospital Zurich, Steinwiesstrasse 75, Zurich, 8032, Switzerland.ORCID 0000-0003-0760-5558
Andreas HahnDepartment of Child Neurology, Justus-Liebig-University Gießen, Gießen, Germany.
Julia B HennermannVilla Metabolica, Center for Pediatric and Adolescent Medicine, University Medical Center Mainz, Mainz, Germany.
Florian B LaglerInstitute for Inherited Metabolic Diseases, Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria.
Dorothea MöslingerDepartment of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Charlotte PfrimmerDepartment of Child Neurology, Justus-Liebig-University Gießen, Gießen, Germany.
Marianne RohrbachDivision of Metabolism, Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Steinwiesstrasse 75, Zürich, 8032, Switzerland.
Martina HuemerDivision of Metabolism, Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Steinwiesstrasse 75, Zürich, 8032, Switzerland. martina.huemer@kispi.uzh.ch.ORCID 0000-0002-0590-678X

Funding

Sanofi Sanofi
6 · The paper itself

Abstract

backgroundChildren and adolescents with Pompe disease (PD) face chronic and progressive myopathy requiring time-intensive enzyme replacement therapy (ERT). Little is known about their perspectives on the disease and its treatment. This study explored their perceptions of disease symptoms and functioning status, and more subjective feelings about the impacts on their lives as part of developing a disease-specific questionnaire.

methodsEleven pediatric patients aged 8-18 years and 26 caregivers from six children's hospitals in Germany, Austria, and Switzerland underwent semi-structured interviews. Data were recorded, transcribed using MAXQDA software, and analyzed using qualitative content analysis. A system of meaningful categories was developed.

resultsSixteen main categories were derived across four major thematic areas: perceptions of symptoms and limitations, experiences to do with the biopsychosocial impact of PD, treatment experiences, and general emotional well-being/burden. Participants demonstrated broad heterogeneity in symptom perceptions such as muscle weakness, breathing difficulties, pain, and fatigue. Emotional appraisals of limitations were not directly proportional to their severity, and even comparatively minor impairments were often experienced as highly frustrating, particularly for social reasons. The main psychosocial topics were social exclusion vs. inclusion and experiences to do with having a disease. The main finding regarding treatment was that switching ERT from hospital to home was widely viewed as a huge relief, reducing the impact on daily life and the burden of infusions. Emotional well-being ranged from not burdened to very happy in most children and adolescents, including the most severely affected.

conclusionThis study provided qualitative insights into the perceptions and experiences of pediatric PD patients. Interestingly, biopsychosocial burden was not directly related to disease severity, and tailored psychosocial support could improve health-related quality of life. The present findings ensure the content validity of a novel questionnaire to be tested as a screening tool to identify patients in need of such support.

Indexed as

CaregiversGlycogen Storage Disease Type IIAdolescentChildEnzyme Replacement TherapyFemaleHumansMaleQualitative ResearchQuality of LifeSurveys and QuestionnairesConcept elicitation interviewsContent analysisContent validityFunctioning, disability, and healthHealth-related quality of lifeInborn errors of metabolismLysosomal storage diseasesMuscle weaknessPediatric patientsQualitative analysis

Identifiers

PMID39342352
PMCPMC11438293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.